Annual CFF
$6.01 M
-$36.14 M-85.73%
31 December 2022
Summary:
Zynerba Pharmaceuticals annual cash flow from financing activities is currently $6.01 million, with the most recent change of -$36.14 million (-85.73%) on 31 December 2022. During the last 3 years, it has fallen by -$24.84 million (-80.51%).ZYNE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$6700.00
-$1.74 M-100.39%
30 June 2023
Summary:
Zynerba Pharmaceuticals quarterly cash flow from financing activities is currently -$6700.00, with the most recent change of -$1.74 million (-100.39%) on 30 June 2023.ZYNE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$5.32 M
-$682.10 K-11.36%
30 June 2023
Summary:
Zynerba Pharmaceuticals TTM cash flow from financing activities is currently $5.32 million, with the most recent change of -$682.10 thousand (-11.36%) on 30 June 2023.ZYNE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZYNE Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -80.5% | +92.7% | -87.9% |
| 5 y5 years | -79.9% | +90.8% | -88.2% |
ZYNE Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -89.5% | -100.0% | -92.9% |
Zynerba Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$6700.00(-100.4%) | $5.32 M(-11.4%) |
| Mar 2023 | - | $1.73 M(+332.9%) | $6.00 M(-0.2%) |
| Dec 2022 | $6.01 M(-85.7%) | $399.40 K(-87.5%) | $6.01 M(+7.1%) |
| Sept 2022 | - | $3.20 M(+373.6%) | $5.61 M(+141.6%) |
| June 2022 | - | $675.40 K(-61.2%) | $2.32 M(+42.5%) |
| Mar 2022 | - | $1.74 M(>+9900.0%) | $1.63 M(-96.1%) |
| Dec 2021 | $42.16 M(+36.6%) | $0.00(-100.0%) | $42.16 M(-4.3%) |
| Sept 2021 | - | -$92.00 K(+408.3%) | $44.05 M(-0.2%) |
| June 2021 | - | -$18.10 K(-100.0%) | $44.14 M(-38.2%) |
| Mar 2021 | - | $42.27 M(+2130.6%) | $71.41 M(+131.4%) |
| Dec 2020 | $30.85 M(-31.8%) | $1.89 M(<-9900.0%) | $30.85 M(+6.4%) |
| Sept 2020 | - | -$4000.00(-100.0%) | $28.99 M(+0.2%) |
| June 2020 | - | $27.25 M(+1491.7%) | $28.92 M(+0.1%) |
| Mar 2020 | - | $1.71 M(+5823.9%) | $28.88 M(-36.2%) |
| Dec 2019 | $45.25 M(+51.1%) | $28.90 K(-139.6%) | $45.25 M(+0.2%) |
| Sept 2019 | - | -$72.90 K(-100.3%) | $45.14 M(-40.0%) |
| June 2019 | - | $27.21 M(+50.5%) | $75.23 M(+56.7%) |
| Mar 2019 | - | $18.08 M(<-9900.0%) | $48.02 M(+60.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $29.94 M(-47.9%) | -$76.50 K(-100.3%) | $29.94 M(-9.3%) |
| Sept 2018 | - | $30.01 M(>+9900.0%) | $33.01 M(+1042.6%) |
| June 2018 | - | $0.00(0.0%) | $2.89 M(-11.3%) |
| Mar 2018 | - | $0.00(-100.0%) | $3.26 M(-94.3%) |
| Dec 2017 | $57.50 M(+475.0%) | $3.00 M(-2880.1%) | $57.50 M(-2.9%) |
| Sept 2017 | - | -$107.80 K(-129.3%) | $59.22 M(-8.3%) |
| June 2017 | - | $367.50 K(-99.3%) | $64.61 M(+0.6%) |
| Mar 2017 | - | $54.25 M(+1050.6%) | $64.25 M(+542.4%) |
| Dec 2016 | $10.00 M(-76.3%) | $4.71 M(-10.8%) | $10.00 M(+91.3%) |
| Sept 2016 | - | $5.29 M(-9013.8%) | $5.23 M(-87.6%) |
| Dec 2015 | $42.19 M(+231.2%) | -$59.30 K(-100.1%) | $42.19 M(-13.3%) |
| Sept 2015 | - | $42.30 M(<-9900.0%) | $48.68 M(+306.7%) |
| June 2015 | - | -$20.60 K(-37.6%) | $11.97 M(-3.4%) |
| Mar 2015 | - | -$33.00 K(-100.5%) | $12.39 M(-2.7%) |
| Dec 2014 | $12.74 M(>+9900.0%) | $6.44 M(+15.2%) | $12.74 M(+102.2%) |
| Sept 2014 | - | $5.59 M(+1290.3%) | $6.30 M(+785.6%) |
| June 2014 | - | $401.90 K(+29.9%) | $711.30 K(+129.9%) |
| Mar 2014 | - | $309.40 K | $309.40 K |
| Dec 2013 | $109.50 K | - | - |
FAQ
- What is Zynerba Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Zynerba Pharmaceuticals?
What is Zynerba Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ZYNE is $6.01 M
What is the all time high annual CFF for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high annual cash flow from financing activities is $57.50 M
What is Zynerba Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ZYNE is -$6700.00
What is the all time high quarterly CFF for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high quarterly cash flow from financing activities is $54.25 M
What is Zynerba Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ZYNE is $5.32 M
What is the all time high TTM CFF for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high TTM cash flow from financing activities is $75.23 M